AI cancer diagnostic tools get FDA green light, promising clinical study results
The news: Two important developments related to AI-based cancer diagnosis surfaced on Friday:
1. Memorial Sloan Kettering spin-out Paige has obtained FDA clearance for their AI-based clinical decision support tool for detecting prostate cancer.
- The tool analyzes digital images of tissue sample slides to help pathologists reduce the time it takes to identify cancer and has helped improve prostate cancer detection by 7.3%.
2. NYU Langone Health released the results of a study showing that its AI tool for breast cancer imaging improved diagnostic accuracy:
- The AI tool improved the ability of radiologists to correctly identify breast cancer by 37% and reduced the need for additional tissue samples by 27%.
Why is this important: Breast cancer and prostate cancer are among the The most common cancers in the United States and cancer is the second leading cause of death in the United States.
- The annual cost of cancer care is over $ 150 billion in the United States– and this should increase with the aging of the population, through the National Cancer Institute.
Trend research: The integration of AI into medical imaging systems is emerging as a promising approach to produce early diagnoses of cancer (which can often save lives).
- For example, in September 2020, Google cloud contracted with the US Department of Defense to develop an AI-based screening system that improves the accuracy of cancer diagnoses.
- AstraZeneca invested in a startup that applies AI technology to medical images to increase early diagnosis of lung cancer in December 2020.
- And just last August, Health Coverage raised $ 25 million to expand its line of AI-based imaging diagnostic solutions.
The overview: AI investments in cancer care are only accelerating across hospitals and healthcare systems, and positive traction like the FDA’s seal of approval and encouraging clinical trial results will only do the job. advance the needle faster.
- 56% of healthcare executives from provider, life sciences and payers organizations said they have accelerated their AI plans in response to the pandemic, through Optum’s survey of AI in healthcare.
- And 55% rank improving health outcomes and patient experiences as the biggest impact of their AI investments.